How can the findings from clinical trials and observational studies be translated into practical recommendations?

The registry will monitor pregnancy outcomes. Please see full Prescribing Information for ABRYSVO. INDICATIONS. ABRYSVO is a vaccine indicated for: the ... It is used in people aged from 2 years who will be visiting areas with high risk of cholera. Cholera is caused by the bacterium Vibrio cholerae (V. cholerae), ... Our observational studies examine the effects of medications and health conditions during pregnancy. Moms can help improve product safety information and shape ... Detailed product information. How it works. How to use. Ingredients. Warnings. Storage & Other Information ... How do I use the suppository? What does "retain" ... Mar 18, 2016 ... This information will help formulate global policies for use of the vaccine at higher temperatures, resulting in easier distribution and ... The first effective oral cholera vaccine was Dukoral, developed in Sweden in the 1980s. For the first six months after vaccination it provides about 85% ... It has been reported that vaccination can reduce the risk of contracting pertussis by 80% to 85%. - More information. ・World Health Organization (WHO): ... For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI. Dukoral®. Active ingredient ... For adults ages 19 to 64 years ... This table summarizes general eligibility information for 12 vaccines for patients ages 19 to 64 years of age. ... Can be given ... Data Sheet · Consumer Medicine Information. DUKORAL® is a registered trademark of Valneva Sweden AB. FERINJECT® | (ferric carboxymaltose) 50 mg/mL solution for ...